The market for PTCA balloons is expanding, as these devices are frequently used in angioplasty procedures to open blocked or narrowed coronary heart arteries. Notably, drug-coated, scoring, and cutting balloons are increasingly being used either as alternatives to or in conjunction with stenting. The need to prepare the target coronary vessel for stent implantation and address in-stent restenosis established them as an essential tool in interventional cardiology. The balloons are being designed with higher burst pressure, better flexibility, and enhanced crossing ability. The number of heart procedures and the availability of cutting-edge medical care in emerging nations are increasing, which supports the demand.
Moreover, the prohibitive cost of devices and the lack of reimbursement in some markets for services remains a key restraint since it limits their use to higher-income countries. Increasingly, physicians are selecting balloon types based on patient and lesion characteristics, which is driving innovation and creating opportunities for more specialized products in this evolving PTCA Balloons Market.
You can easily get a sample PDF of the report – https://www.businessmarketinsights.com/sample/BMIPUB00031927
PTCA Balloons Market Segmentation Analysis
Key segments that contributed to the derivation of the PTCA balloons market analysis are product type, application, and end user.
- By product type, the PTCA balloons market is segmented into normal balloons, drug coated balloons, cutting balloons, and scoring balloons. The drug coated balloons segment dominated the market in 2024.
- By application, the PTCA balloons market is segmented into coronary artery disease and peripheral artery disease. The coronary artery disease segment held a larger share of the market in 2024.
- By end user, the market is segmented into hospitals, ambulatory surgical centers, cardiac catheterization labs, and specialty clinics. The hospitals segment held the largest share of the market in 2024.
PTCA Balloons Market Drivers and Opportunities:
Rising Adoption of Drug-Coated Balloons (DCBs)
Drug-coated balloons are being used more often alongside stents for some coronary and peripheral procedures. They release drugs into the artery wall while the balloon is inflated, which helps stop the vessel from narrowing again. No implant is left behind, which is useful in small vessels, bifurcations, or cases where a stent has already been used and failed.
Many doctors now turn to DCBs for both first-time treatments and repeat procedures. They open the artery and deliver the drug in a single step. Without a stent, the chance of late thrombosis is lower, and patients may not need long courses of dual antiplatelet therapy. With more studies showing good results and approvals widening, its usage is growing. As confidence builds, DCBs are likely to become a bigger part of coronary and peripheral artery disease treatment. Thus, driving the market in the near future.
Advancements in Non-Compliant Balloon Technology
Non-compliant (NC) balloons have improved a lot in recent years in terms of design, materials, and performance. This has strengthened their role in complex coronary procedures. They expand to a fixed size, even at high pressures, which allows accurate vessel sizing and proper lesion preparation before stenting. New designs make them easier to track and more flexible, helping them cross calcified or twisted vessels without losing shape or causing damage. Higher burst pressure tolerance lets them open stubborn blockages effectively. This makes them especially useful for post-dilatation, ensuring the stent is fully expanded and well seated.
Manufacturers are also making thinner balloon profiles and using advanced coatings to reduce friction and improve crossing ability. These upgrades help doctors achieve better results, particularly in difficult cases. With these advancements becoming more common, NC balloons are now seen as essential in both standard and complex coronary interventions, and their demand is rising worldwide.
PTCA Balloons Market News and Key Development:
The PTCA balloons market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the PTCA balloons market are:
- In May 2025, Boston Scientific Corporation announced CE Mark and U.S. Food and Drug Administration (FDA) approval of its NC Quantum Apex™ PTCA Dilatation Balloon Catheter.
- In March 2024, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
Get Premium Research Report at: https://www.businessmarketinsights.com/buy/BMIPUB00031927
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact us:
- If you have any questions about this report or would like further information, please contact us:
- Contact person: Ankit Mathur
- Email: sales@businessmarketinsights.com
- Phone: +16467917070
-
-
-
-